3056-17-5
3056-17-5 structure
- Name: Stavudine
- Chemical Name: stavudine
- CAS Number: 3056-17-5
- Molecular Formula: C10H12N2O4
- Molecular Weight: 224.213
- Catalog: API Synthetic anti-infective drugs Antiviral drugs
- Create Date: 2018-02-15 08:00:00
- Modify Date: 2026-07-01 17:25:45
-
Stavudine is a nucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.Target: HIV RT; NRTIsStavudine is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it [1]. Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes [2].Clinical indications: HIV-1 infection FDA Approved Date: June 24, 1994 Toxicity: peripheral neuropathy; lipodystrophy
| Name | stavudine |
|---|---|
| Synonyms |
1-((2R,5S)-5-HYDROXYMETHYL-2,5-DIHYDRO-FURAN-2-YL)-5-METHYL-1H-PYRIMIDINE-2,4-DIONE
2',3'-Didehydro-3'-deoxythmidine a nucleoside analog that inhibits reverse transcriptase Sanilvudine 1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione 1-(2,3-Dideoxy-β-D-glycero-2-pentenofuranosyl)thymine 2',3'-Didehydro-2',3'-dideoxythymidine d4T 2',3'-Anhydrothymidine 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine Stavudine Sanilvudine sanilvudine Stavudine(DT4) 1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidin-2,4(1H,3H)-dion Stavudine SysteM Suitability Mixture Stavudine Impurit Ⅱ: 2',3'-Didehydro-3'-deoxythymidine, 3'-Deoxy-2'-thymidinene( Stavudine) 2',3'-dideoxy-2',3'-didehydrothymidine 1-[(2R,5S)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]-5-méthylpyrimidine-2,4(1H,3H)-dione 2',3'-Didehydro-3'-deoxythymidine> Stavudine CRS 2’,3’-didehydro-3’-deoxy-thymidin 2',3'-Anhydrothymidine STAVUDINE 2μ,3μ-Anhydrothymidine, d4T, Stavudine, 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine 2',3'-Didehydro-3'-deoxythyMidine, 3'-Deoxy-2'-thyMidinene Stavir 2',3'-Dideoxythymidiene 2’,3’-dideoxy-2’,3’-didehydrothymidine Thymidine, 2'', 3''-didehydro-3''-deoxy STAVUDINE[2'',3''-DIDEHYDRO-3''-DEOXYTHYMIDINE] D 4T (nucleoside) 2',3'-ANHYDROTHYMIDINE Zidovudine Impurity A (Stavudine) Avostav 1-(2,3-dideoxy-β-d-glycero-pent-2-enofuranosyl)thymine 3'-DEOXY-2',3'-DIDEHYDROTHYMIDINE 2'-Thymidinene, 3'-deoxy- (8CI) 1-[(2R,3R,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-cboxamide and 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione Stavudine for system suitability CRS Stavudine //BP 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine 2',3'-Didehydro-3'-deoxythymidine, D4t, BMY-27857, Zerit 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione 2',3'-Didehydro-3'-deoxythyMidine 2'', 3''-DIDEHYDRO-3''-DEOXYTHMIDINE 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione 1-(2,3-Dideoxy-Beta-D-Glycero-2-Pentenofuranosyl)Thymine 3'-deoxythymidin-2'-ene Virostav 4-Hydroxy-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2(1H)-pyrimidinone Stauvidine STAVUDINE(PATENTEDNO-SUPPLY) Zidovudine ImpuritⅡ:Stavudine 3'-Deoxy-2'-thymidinene 2’,3’-Dideoxy-2’,3’-didehydrothymidine, Stavudine Zerit 2',3'-Didehydro-3'-deoxy-D-thymidine BMY-27857 1-(5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) Stauvidine Hydrochloride 2',3'-didehydro-3'-deoxythimidine 1-[2,3-DIDEOXY-BETA-D-GLYCERO-PENT-2-ENOFURANOSYL]THYMINE D4t, BMY-27857, Zerit 1-(2,3-Dideoxy-b-glycero-pent-2-enofuranosyl)thymine D 4T D4T estavudina ZERIT MFCD00132921 1-(2,3-dideoxy-beta-d-glycero-pent-2-enofuranosyl)-thymin Zidovudine IMpurity A 1-(5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL)-5-METHYLDIHYDROPYRIMIDINE-2,4(1H,3H)-DIONE Sanilvudine (JAN) Thymine, 1-(2,3-dideoxy-b-D-glycero-pent-2-enofuranosyl)- (7CI, 8CI) 2',3'-DIHYDRO-2',3'-DEOXYTHYMIDINE 1-[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione Thymine, 1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)- (7CI,8CI) 2',3'-dideoxy-2',3'-didehydrothymine |
| Description | Stavudine is a nucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.Target: HIV RT; NRTIsStavudine is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it [1]. Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes [2].Clinical indications: HIV-1 infection FDA Approved Date: June 24, 1994 Toxicity: peripheral neuropathy; lipodystrophy |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 440.6±55.0 °C at 760 mmHg |
| Melting Point | 159-160°C |
| Molecular Formula | C10H12N2O4 |
| Molecular Weight | 224.213 |
| Flash Point | 220.3±31.5 °C |
| Exact Mass | 224.079712 |
| PSA | 84.32000 |
| LogP | -1.25 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.646 |
| Storage condition | −20°C |
| Stability | Stable. Combustible. Incompatible with strong oxidizing agents. |
| Water Solubility | 5-10 g/100 mL at 21 ºC |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATAMUTATION DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | XP2075000 |
| HS Code | 2938901000 |
| Precursor 7 | |
|---|---|
| DownStream 9 | |
![1-[5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-β-D-glycero-pento-2-enofuranosyl]thymine structure](https://image.chemsrc.com/caspic/057/125440-17-7.png)
![[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methyl acetate structure](https://image.chemsrc.com/caspic/273/77421-68-2.png)
![2,5-Methano-5H,9H-pyrimido[2,1-b][1,5,3]dioxazepin-9-one,2,3-dihydro-3-(hydroxymethyl)-8-methyl-, (2R,3R,5R) structure](https://image.chemsrc.com/caspic/418/15981-92-7.png)
![hydroxy-[[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-oxophosphanium structure](https://image.chemsrc.com/caspic/335/140132-35-0.png)
![[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methyl 2,2-dimethylpropanoate structure](https://image.chemsrc.com/caspic/441/126209-27-6.png)
| HS Code | 2938901000 |
|---|---|
| Summary | HS: 2938901000. 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one. VAT:17.0%. tax rebate rate:13.0%. supervision conditions:None. MFN tarrif:6.5%. general tariff:20.0% |